ARTICLE SUMMARY:
Public investors maintained their interest in medtech—particularly small caps—in the first quarter of 2019, while M&A slowed. Could this be a sign that the sector’s rising valuations are causing prospective acquirers to back off?
If the first quarter US medtech M&A and IPO data are signs of how the rest of this year is going to play out, then the industry is looking at a classic good news/bad news performance.